Kinex News
-
March 4, 2010
Charles E. Lannon was appointed as Vice-Chairman of the Board of Directors at Kinex Pharmaceuticals on March 3, 2010. Mr. Lannon is President of Strategic Advisory, Inc., a consulting firm ... read more
-
February 19, 2010
Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate CancerKinex Pharmaceuticals opened a Phase 2 clinical trial to evaluate the safety and efficacy of KX2-391 in patients with bone-metastatic, castrate-resistant prostate cancer (CRPC) who have not had prior chemotherapy. ... read more
-
January 31, 2010
Kinex Pharmaceuticals has appointed Rudolf Kwan, MD, as Chief Medical Officer. Dr. Kwan has had a successful career in the pharmaceutical industry and brings to Kinex over twenty years of ... read more
-
January 25, 2010
Kinex Pharmaceuticals LLC sold its Series A preferred units to raise $4.075 million in a recent round of financing, its largest single round to date. Since late 2004, the Company ... read more
-
May 27, 2009
Kinex Pharmaceuticals will present results from a Phase 1 clinical study with KX2-391, at the ASCO 2009 Annual Meeting in Orlando, on May 29, 2009. The study was carried out ... read more
-
May 11, 2009
Kinex Pharmaceuticals has been awarded a Phase 2 SBIR Award from the National Cancer Institute to develop biomarkers for its cancer drug KX2-391. The award in the amount of $955,063 ... read more
-
March 19, 2009
Dr. Allen Barnett, Chief Executive Office of Kinex Pharmaceuticals, has been invited by the Biotechnology Industry Organization (BIO) to present at the Second Annual BIO National Venture Conference, taking place ... read more
-
February 2, 2009
Charles E. Lannon was elected to the Board of Directors at Kinex Pharmaceuticals on January 30, 2009. Mr. Lannon is President of Strategic Advisory, Inc., a consulting firm specializing in ... read more
-
December 30, 2008
Kinex Pharmaceuticals has selected KXO2; a compound that will be developed for brain cancer. The orally active compound has demonstrated extraordinary activity in a mouse glioblastoma model. When benchmarked against ... read more
-
November 14, 2008
On Thursday, November 13, 2008 a small plane went down in a Tallahassee, Florida neighborhood, killing Buffalo entrepreneur and Kinex Pharmaceuticals Board Member, Donald Hess and his wife Victoria. “We ... read more
-
October 30, 2008
Kinex Pharmaceuticals recently raised $3.4 million through a private placement among its existing shareholders. This round brings the total raised in equity capital and grants to approximately $15 million, since ... read more
-
September 15, 2008
Buffalo, N.Y., September 15, 2008 – Kinex Pharmaceuticals announced that David Hsia, Ph.D. has been appointed to the Company's Board of Directors. Dr. Hsia is a pharmaceutical veteran. He is ... read more
-
August 29, 2008
Kinex Pharmaceuticals is currently working on a potential new drug for the treatment of brain tumors, in adults and children. This new drug is a follow-up to KX01, which is ... read more
-
May 12, 2008
On May 8, 2008, Dr. David Hangauer, Co-Founder and Senior Vice President of Research and Development at Kinex Pharmaceuticals was presented with the “Inventor of the Year Award” by the ... read more
-
April 14, 2008
Dr. Yahao Bu, a post-doctoral scientist at Kinex Pharmaceuticals, delivered a talk at the 2008 Annual Meeting of the American Association for Caner Research. The Meeting was held in San ... read more
-
March 10, 2008
Kinex Pharmaceuticals closed on its largest round of financing since its inception in 2004. This most recent round of $3.2 million brings the total raised to approximately $9 million. “Current ... read more
-
March 7, 2008
Lyn M. Dyster Ph.D., co-founder and vice president of research operations at Kinex Pharmaceuticals has been appointed to a four-year term on the Board of Directors of the New York ... read more
-
December 12, 2007
Kinex Pharmaceuticals was granted United States Patent No. 7,300,931 B2 on November 27, 2007. The patent entitled “Compositions for Treating Cell Proliferation Disorders” claims composition of matter for new chemical ... read more
-
November 26, 2007
Anti-cancer drug developed here to begin human testing Could be boon for area biotech industry By Henry L. Davis NEWS MEDICAL REPORTER 11/25/07 Tests of a promising anti-cancer drug developed ... read more
-
October 30, 2007
Kinex Pharmaceuticals has announced that its oncology drug, KX2-391, has entered ... read more
Kinex Founders: left to right, Lyn M. Dyster, Ph.D., Allen Barnett, Ph.D. and David G. Hangauer, Ph.D.
-
October 20, 2007
Dr. David Hangauer, Co-Founder and Senior Vice President of Research and Development at Kinex Pharmaceuticals was invited to present at the Cambridge Healthtech Institutes Fifth Annual “Discovery on Target, 2007” ... read more
-
September 10, 2007
Dr. David Hangauer, a Founder and Senior Vice President of Research and Development at Kinex Pharmaceuticals received an award for best poster at the Gordon Conference on Medicinal Chemistry that ... read more
-
July 19, 2007
Kinex Pharmaceuticals was notified today, by the U.S. Food and Drug Administration that its Investigational New Drug, KX2-391, can proceed into Phase 1 Clinical Trials. “The rapid progress we have ... read more
-
June 21, 2007
Kinex Pharmaceuticals LLC, announced today that the Company has filed its first Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for KX2-391 (KX01), an internally ... read more
-
June 15, 2007
Kinex Pharmaceuticals was honored by Insyte Consulting at a reception held at the Albright Knox Art Gallery on June 13, 2007. Insyte Consulting assists Western New York manufacturing and technology ... read more
-
June 7, 2007
Kinex Re-Opened its Series A round of financing to raise additional capital to complete the pre-clincial developent of KXO1 for oncology and to secure funding to commence a Phase 1 ... read more
-
June 7, 2007
Dr. David Hangauer, Senior VP of Research and Development delivered a case study that described the discovery of KXO1, the Company's clinical drug candidate for oncology. The conference, "Protein Kinase ... read more
-
April 23, 2007
Kinex scientists presented recent data on the discovery and development of KXO1, at the American Association for Cancer Research Annual Meeting in Los Angeles, on April 16, 2007. KXO1 is ... read more
-
April 22, 2007
Dr. David Hangauer, a co-founder and senior vice president of research development at Kinex Pharmaceuticals has recently received several honors. The Niagara Frontier Intellectual Property Law Association and the Technical ... read more
-
April 5, 2007
The Annual Meeting of Shareholders will take place on April 24, 2007 at 9 am at our offices in Buffalo, NY. For directions and accommodation information, go to www.kinexpharma.com/directions. read more
-
October 31, 2006
US Patent No.7,129,225 entitled “Protection Against and Treatment of Hearing Loss” was issued on October 31, 2006. The importance of this patent is that it describes the use of Src ... read more
-
October 1, 2006
Kinex Pharmaceuticals is the recipient of a $107,000 Phase 1 SBIR grant from the National Cancer Institute. The grant entitled “Commercial Development of Src Kinase Inhibitors for Oncology” will be ... read more
-
September 30, 2006
Since its inception, approximately 2 years ago, Kinex Pharmaceuticals has raised approximately $4 million via Private Placements and Grants. The Company has used these funds to focus on the pre-clinical ... read more
-
July 1, 2006
Kinex Pharmaceuticals is a new tennant in the $300 million New York State Center of Excellence (COE) in Bioinformatics and Life Sciences. This 300,000 square foot facility was built with ... read more
-
April 1, 2006
Kinex Pharmaceuticals has identified a highly selective inhibitor of Src kinase and will develop the compound for uses in oncology. The compound, KXO1, is an orally active small molecule that ... read more
-
March 8, 2006
US Patent 7,005,445 B2 entitled “Protein Kinase and Phosphatase Inhibitors and methods for Designing Them” issued on February 28, 2006. This is an important patent for Kinex Pharmaceuticals that describes ... read more
-
January 6, 2006
Kinex Pharmaceuticals has received a grant from The University at Buffalo (UB) CAT. This organization is part of NYSTAR (New York State Office of Science, technology and Academic Research)and it ... read more
-
January 4, 2006
Kinex Pharmaceuticals closed a round of private equity financing totaling $700,000. The Company has raised more than $2 million from angel investors and regional economic development agencies through private placements, ... read more
-
September 14, 2005
Kinex Pharmaceuticals received an investment of $200,000 from The Niagara Region Ventures Fund. The fund is part of the ECIDA Financing Group that supports private investment that expands or retains ... read more
-
September 6, 2005
Buffalo, NY, September 6, 2005 – Kinex Pharmaceuticals, a biopharmaceutical company developing small molecule drugs for the treatment of cancer, announced today that KX2-377 has been selected as a lead ... read more
-
August 17, 2005
Kinex Pharmaceuticals recently entered into an agreement with The Research Foundation of the State University at New York and Roswell Park Cancer Institute that provides the Company exclusive worldwide rights ... read more
-
August 3, 2005
Kinex Pharmaceuticals, LLC received a $200,000 equity investment from the Western New York Business Development Fund. The BDF is a program funded through a partnership of the Empire State Development ... read more
-
August 3, 2005
Kinex Pharmaceuticals was recognized by The University at Buffalo at a Scholars, Inventors and Entrepreneurs Reception in the Center for Tomorrow on the UB North (Amherst) Campus on May 26, ... read more
-
September 24, 2004
Download PDF
-
September 10, 2004
Kinex Pharmaceuticals announced today that it entered into an exclusive licensing arrangement with SUNY at Buffalo on September 9, 2004. Under this agreement, Kinex gains rights to worldwide patents that ... read more
-
August 20, 2004
Kinex Pharmaceuticals has announced today that Mr. Donald A. Hess has been elected to join its Board of Directors. Hess, an MIT- educated, Buffalo, NY-based entrepreneur, co-founded Amherst Systems. Amherst ... read more
-
August 1, 2004
Kinex Pharmaceuticals announced today that it has closed its first round of private equity financing on July 31, 2004. Investors from New York, California and New Jersey participated. The funds ... read more
-
July 1, 2004
Download PDF
-
July 1, 2004
Kinex Pharmaceuticals was honored at a Scholars, Inventors and Entrepreneurs Reception held on May 26, 2004 by the University and Buffalo and the Office of Science Technology Transfer and Economic ... read more
-
July 1, 2004
Over a period of just 4 months (February-May, 2004), and with a very modest expenditure of funds, Kinex has made very significant progress toward the goal of selecting a drug ... read more
-
June 15, 2004
Download PDF
-
January 25, 2004
The Buffalo News reported that the University of Buffalo's fledgling efforts tp translate faculty research into commercially viable products matured in 2003. Research innovations produced in UB laboratories are generating ... read more
-
December 13, 2003
Contact: Lois Baker, ljbaker@buffalo.edu Phone: 716-645-5000 ext 1417 Fax: 716-645-3765 BUFFALO, N.Y. -- Six hundred Marines at Camp Pendleton in California will undergo two weeks of war games in the ... read more
-
October 27, 2003
From Lab Bench to Board Room: UB Chemist's Powerful Approach to Anti-Cancer Compounds Makes the LeapIn a classic example of scientific research that has successfully outgrown the university lab where it was born, a University at Buffalo professor’s unique method for designing and synthesizing anti-cancer ... read more
-
October 26, 2003
On October 26, The Buffalo News reported that Dr. Allen Barnett will become CEO of Kinex Pharmaceuticals, a company working to develop a new generation of cancer drugs. Dr. Barnett, ... read more